AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 6 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Neutralizing antibodies against human papillomavirus 16 (HPV16) appear to cause regression of cervical intraepithelial (CIN) lesions and may even eliminate lesions in some cases.
Kei Kawana and colleagues at the University of Tokyo assigned 76 women to one of four categories based upon their cervical pathology, normal (n=7), CIN1 (n=37), CIN2 or CIN3 (n=19), or cervical cancer (n=13). Serum samples from the subjects were tested for neutralizing antibodies against HPV16 using HPV16-pseudovirions.
Women with normal cervical pathology were significantly more likely (p
The amount of HPV DNA was significantly lower in women with neutralizing antibodies compared with women who did not have neutralizing antibodies (p=0.05).
"The neutralizing antibodies seem to have a role in deterring HPV-related cervical lesions from progressing to CIN2/3 by inhibiting the infection with de novo replicated HPV," reported Kawana and associates. "This study further suggests that HPV vaccine to induce the neutralizing antibodies may be effective in eliminating CIN lesions, especially in the neutralizing-antibody-negative cases." (Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical ...
Source: HighBeam Research, HPV16 antibodies cause regression of cervical neoplasia.